Home/Pipeline/SAB-176

SAB-176

Influenza

Phase 1Completed

Key Facts

Indication

Influenza

Phase

Phase 1

Status

Completed

Company

SAB Biotherapeutics

About SAB Biotherapeutics

SAB Biotherapeutics' mission is to leverage its proprietary DiversitAb™ platform to develop a new class of fully human polyclonal antibody therapeutics. Its key achievement is the creation of a validated, scalable production system using transgenic cattle, which has advanced multiple candidates into clinical trials, including a program for COVID-19. The company's strategy is to clinically validate its platform in autoimmune disease, starting with type 1 diabetes, and expand into other areas of high unmet need where polyclonal antibodies offer a differentiated therapeutic profile. As a public company, SAB is focused on executing its clinical milestones to demonstrate proof-of-concept and attract strategic partnerships.

View full company profile

Therapeutic Areas

Autoimmune Diseases Infectious Diseases

Other Influenza Drugs

Drug	Company	Phase	Status
PanCytoVir™ (oral probenecid)	TrippBio	IND Submitted	Active
Mimotopes-004	Mimotopes	Preclinical	Active
Next-Gen / Universal Flu Vaccines	CSL Seqirus	Research / Early Clinical	Active
Oseltamivir 75 mg	MSN Laboratories	Commercial	Active
AI Programme - Influenza	Poolbeg Pharma	Discovery	Active - Target/Candidate ID
Influenza Antibodies	new/era/mabs	Research/Pre-clinical	Active
Influenza Countermeasure Program	DynPort Vaccines	Not Specified	Active
Influenza Vaccine	Medigen	Preclinical	Active
Nasal Influenza Vaccine	Abera Bioscience	Pre-clinical	Active
Zapnometinib (ATR-002)	Atriva Therapeutics	Phase 2	Active
EV25	Eradivir	Pre-clinical	Active
Not Specified	New Amsterdam Sciences	Pre-clinical	Active